Patients with NSCLC bearing typical EGFR mutations have better outcomes when they are treated with approved first generation (reversible inhibitors erlotinib and gefitinib), second generation (irreversible inhibitors afatinib and dacomitinib) or third generation (T790M targeting inhibitors osimertinib and lazertinib) EGFR TKIs than with chemotherapy (summarized in Table 1). Here, EGFR is linked to non-small cell lung carcinoma.